Slides
Page 1
Investor Presentation Q1 FY26 Poly Medicure Ltd. 8th August 2025 1
Page 2
Disclaimer This presentation and the accompanying slides (“Presentation”) by Poly Medicure Limited (the “Company”) are for informational purposes only and do not constitute an offer, recommendation, or invitation to purchase or subscribe for any securities. They should not be relied upon for any contract or binding commitment. No securities offering will be made except through a statutory offering document with detailed information about the Company. The Company has prepared this Presentation based on reliable information but makes no representation or warranty, express or implied, about its accuracy, completeness, fairness, or reasonableness. This Presentation may not include all material information. Any liability for the contents or omissions is expressly excluded. Some statements may discuss the Company’s market opportunity and business prospects as forward-looking statements, which are not guarantees of future performance and are subject to risks, uncertainties, and assumptions that are difficult to predict. These include economic performance, industry competition, strategic implementation, technological changes, revenue fluctuations, market preferences, and exposure to market risks. Actual results may differ materially from those expressed or implied. The Company assumes no obligation to update any forward-looking information. Any third-party forward-looking statements and projections included are not adopted by the Company, and it is not responsible for them. 2 -;:, POLYMED
Page 3
Agenda Agenda Slide # YoY Performance Summary Q1 FY26 5 Key Updates 7-13 Consolidated Financial Performance Summary 15 Sales Performance Analysis 16-17 Return ratios 18 Shareholding Pattern 19 Polymed Overview and Way forward 21-32 3
Page 4
YoY performance summary of Q1 FY26 Agenda 4
Page 5
Consolidated Performance Summary Q1 FY 26 Revenue Figs in Rs. Crs unless specified 403.2 384.8 4.8% Numbers are rounded to closest round digit *Excludes the amount raised through QIP in August 2024, EBIT has been computed after excluding the treasury income generatedfrom the QIP Funds; Calculated based on trailing 12 months performance 106.1 103.8 2.1% 26.3 27.0 70bps 93.1 74.0 25.5% Q1,FY26 Operating EBITDA EBITDA % PAT Q1,FY25 Net Cash 1,248.6 Increase in Sales Associates 22 # of Patents 334 RoCE* 22.4% 5
Page 6
Key Updates Agenda 6
Page 7
• A total of 1350+ stents were successfully implanted from April’25 to Jul’25, with positive feedback received from patients and clinicians. • Initiated an Open-label, multicentre, single arm, clinical investigation to evaluate performance and safety of RisoR Everolimus Eluting Stent System (PACIFIER) across India and Europe on 2,000 patients. • YTD July 25 sold ~130 dialysis machines—reinforcing our market presence • Signed two contract manufacturing contracts with companies based in US and Hong Kong in the Vascular Access and Pain Management segment. • Established our wholly owned subsidiary in Brazil to expand presence; over the next few quarters we will expand our direct pr esence in this key South American market. • Awaiting the allotment letter from YEIDA for a 7.16 acre plot at the Medical Devices Park, following the receipt of the Lette r of Comfort from Invest UP • Approval received from Shareholders for appointment of Mr. Vishal Baid as Executive Director and approval from Board for appo intment for Mr. PK Gupta (President - Operations) as Executive Director on the Board • Enhancing usage of AI to optimize performance and learning and development of staff • Conducted 6 sessions on “IV talks”- our clinical engagement program with nursing leaders , imparting training to 6,000+ nurses Key Business Updates • Consolidated Q1 FY26 revenue growth 4.8%; Q1 FY26 Domestic revenue growth is 20.1%. • Q1 FY26 Consolidated Operating EBITDA and PAT Growth of 2.1% and 25.5% respectively; Q1 Operating EBITDA margin of 26.3%, within the EBITDA margin guidance of 25% - 27% for FY26 • Adequate liquidity of Rs 1,248.6 Crs as at Jun 30, 2025; Capex spend of Rs. 95 Crs in Q1 FY26 on target to meet the capex budget of Rs. 250 Crs in FY26. Financial Highlights Key Updates • Launched over 7 new products in Q1 FY 26 • R&D team strength of ~65Product • Mr Himanshu Baid, Managing Director, Poly Medicure, awarded the “Healthcare Entrepreneur” of the year 2025 by Financial Express • Poly Medicure, awarded the “Medical devices provider” of the year 2025 by Financial Express • Poly Medicure, awarded “Excellence in Medical Equipment Innovation” by Informa Markets at India Health Next • “Leading brand in medical devices” at Elets Healthcare and Innovation Summit • Awarded “Bhamashah Award” by Govt. of Rajasthan, Education Department for CSR initiative Awards 7
Page 8
• Open Label • Multicentric • Single Arm • Post Market (India) • Pre Market (EU) Design • Enrolment: 12 months • Total Study: 24 months Duration • 1 Month • 6 Month • 9 Month (including QCA/OCT) • 12 Month Follow up Patients: 2000 • Europe:40 • India: 1960 • QCA:100 • OCT: 50 Patients Study on performance and safety of RisoR Stent Study Title: An Open-label, Multicentre, Single arm, Clinical Investigation to Evaluate Performance and Safety of RisoR Everolimus Eluting Stent System (PACIFIER) India’s First international Clinical registry of 2000 patients 50Sites(India)+1Site(Italy) Dr. Praveen Chandra Chairman – Interventional Cardiology Medanta-The Medicity, Gurugram, Haryana (National Lead Investigator- India) 8
Page 9
Appointment of Mr. Vishal Baid as Executive Director approved by Shareholders Some of his key contributions in the organization over the years are summarized below: • Driving automation in the production processes by identifying new technologies, helping in driving cost efficiencies and building global competitive advantages for the company. • Leading the development and management of the manufacturing footprint in the Jaipur region and currently oversees all operations of the manufacturing plants in Jaipur. • Developing diverse vendor relationships for both raw material and capital equipment. • Leading cross-functional coordination across marketing, procurement, product development and operations to align business priorities with growth strategy. • Strengthening the company’s institutional sales network, building deep customer relationships with key accounts and driving sales in the domestic market. • Contributing to the launch and commercial scale-up of various high-growth product segments such renal care, critical care and cardiology. Experience: Mr. Vishal Baid has over two decades of multifaceted leadership experience in the global medical devices industry and has played a pivotal role in the strategic growth and international expansion of Poly Medicure Limited. His new Role in Company: • To drive growth in product development and focus on business development in India. • Responsible for overseeing the strategic growth, operations, and profitability of the Jaipur SEZ and Haridwar plant, ensuring efficient production, strong quality control, and revenue maximization to support overall business goals and market competitiveness. Association with Poly Medicure Ltd: He has been associated with Poly Medicure for last 14 years and prior to his appointment as Executive Director, was designated as Sr. President (Sales and Marketing). 9
Page 10
Approval by the Board for appointment of Mr. PK Gupta as Executive Director Some of his key contributions in the organization over the years are summarized below: • He recognizes the potential of cutting-edge technologies to create products that address unmet medical needs, improve patient outcomes, and enhance the quality of care. • Lead end to end manufacturing operations across multiple plants. • Implement operational excellence strategies to improve productivity and reduce waste. • Collaborate with cross-functional teams in R&D, Quality, Procurement, and Marketing. • Drive automation and digital transformation in manufacturing processes. • Ensure compliance with global regulatory and quality standards (ISO, CE, FDA). • Manage large teams of engineers, supervisors, and technicians. Experience: Mr. PK Gupta has 35 years of experience in the medical devices and manufacturing industry including 17 years in Poly Medicure Ltd. Before Joining Poly Medicure, he has experience with various companies and industries, including HMD, Dalmia Electronics, LML Ltd. His new Role in Company: Mr. Pankaj Kumar Gupta thrives on hands-on involvement, often working in the field and engaging directly with suppliers to drive Poly Medicure's growth and direction. His approachable leadership style and deep engagement with the team foster a motivated and inspired workforce, empowering them to achieve their goals and push boundaries. As the medical devices industry continues to evolve rapidly, Mr. Gupta's leadership and vision enable Poly Medicure to stay ahead of the curve, leveraging his expertise to navigate challenges and capitalize on opportunities. Association with Poly Medicure Ltd: He joined as a senior manager in 2008 and rose to become President - Operations, leading key operational advancements. His strategic leadership significantly contributed to company’s growth 10
Page 11
Enhance Usage of AI to optimize performance AI is being integrated into our manufacturing operations as we move towards smart manufacturing. From vision - control to process optimization , AI enhances precision & efficiency Our AI-powered initiative is delivering immersive training experiences that replicate real-world customer interactions, product demonstrations, and trouble shooting. In Manufacturing Processes In Learning and Development 11
Page 12
Clinical Engagement Programs A Joint Program with INS 6 sessions , 6000+ Nurses 12
Page 13
Participation in International Exhibitions WHX, Miami Hospitalar, Brazil Medi Pharm Expo, Vietnam WHX, Kuala Lumpur 13
Page 14
Consolidated Financial Performance Summary Agenda 14
Page 15
Consolidated Financial Performance Summary Re- classification has been done wherever necessary Figs in Rs. Cr. unless specified Particulars Q1 FY 26 Q1 FY 25 Growth % Revenue from Operations 403.2 384.8 4.8% Cost of Good Sold (127.2) (128.3) (0.8%) Gross Profit 276.0 256.5 7.6% Gross Profit % 68.4% 66.7% 170bps Employee Benefit Expenses (75.1) (69.5) 8.1% R&D Expenses (6.7) (5.6) 20.0% Other Expenses (88.0) (77.6) 13.6% Total Operating Expenses (297.1) (281.0) 5.8% Operating EBITDA 106.1 103.8 2.1% Operating EBITDA % 26.3% 27.0% (70bps) Other Income 41.7 16.9 146.4% Depreciation (23.3) (19.5) 19.1% Finance Cost (3.0) (3.2) (6.7%) Profit Before Tax & share of net profit of an associate 121.6 98.0 23.9% Share of Profit of an Associate 1.3 0.4 205.2% PBT 122.9 98.5 24.7% Tax (29.9) (24.4) 22.3% PAT 93.1 74.0 25.5% PAT % 20.9% 18.4% 250bps EPS – Basic (in Rupees) 9.2 7.7 18.8% EPS – Diluted (in Rupees) 9.2 7.7 18.8% 15
Page 16
Consolidated Sales Performance Analysis Numbers are rounded to closest round digit Figs in Rs. Crs unless specified 31% 27% 33% 37% 36% 36% Q1 FY 26 Q1 FY 25 India Europe RoW Particulars Q1 FY 26 Q1 FY 25 Growth % Domestic 125.7 104.7 20.1% International 275.1 277.6 (0.9%) Other Operating Revenue 2.4 2.5 (3.6%) Total Operating Revenue 403.2 384.8 4.8% Geographical Revenue Mix India 125.7 104.7 20.1% Europe 133.3 142.9 (6.7%) RoW 141.8 134.7 5.3% Other Operating Revenue 2.4 2.5 (3.6%) Total Operating Revenue 403.2 384.8 4.8% Revenue Mix- Domestic & International Geographical Segment 16 31% 27% 69% 73% Q1 FY 26 Q1 FY 25 Domestic International
Page 17
Segment Wise Sales Performance Analysis Figs in Rs. Crs unless specified Particulars Q1 FY 26 Q1 FY 25 Growth % Infusion Therapy 251.8 256.2 -1.7% Renal 43.5 29.8 46.2% Others 107.9 98.8 9.3% Total Operating Revenue 403.2 384.8 4.8% 63% 67% 11% 8% 26% 25% Q1 FY26 Q1 FY25 Infusion Therapy Renal Others Revenue Mix by Segment ▪ Renal Care- Sold ~130 Dialysis machine from Apr’25 to Jul’25, expanding presence to ~170 cities through strategic alliance with top dialysis chains. ▪ Under the vision of Govt. of India “Pradhan Mantri National Dialysis Program” has been implemented in 751 districts, under which 1,704 dialysis centres are operational. Expansion of network to the levels of community health centres being undertaken by National Health Mission(NHM). 17
Page 18
Return Ratios * * Excludes the amount raised through QIP in August 2024, EBIT has been computed after excluding the treasury income generated from the QIP Funds ** Calculated based on trailing 12 months performance ROCE ROE 19% 23% 23%* 22%** FY 23 FY 24 FY 25 Jun'25 15% 19% 18%* 17%** FY 23 FY 24 FY 25 Jun'25 18
Page 19
Shareholding Pattern as on June 30th 2025 Promoter and Promoter Group 62.4% Mutual Funds 7.3% AIF 1.7% Insurance Companies 2.7% FPI 11.4% Others 14.5% 19
Page 20
Corporate Overview Agenda 20
Page 21
Polymed Key Differentiators ▪ Legacy – Operating since 1997 ▪ Leadership – Second fastest growing Medtech Company in India in terms of revenue * ▪ Focus on innovation : Granted 334 patents in India and globally ▪ Manufacturing powerhouse – Backward integrated manufacturing facilities with annual capacity of over 1.8bn devices across 200+ product categories; 12 operational plants and 3 under construction ▪ Global Business – ~70% of revenue from International business ▪ Established Distribution Network – 530+ Sales associates and 630+ distributors in India; 260 distributors globally ▪ Solid Financial Strength and Liquidity: Zero Net Debt Balance sheet with significant cash reserves of Rs. 1248.6 Cr. *Source: latest company fillings 21 -;:, POLYMED
Page 22
Polymed at a Glance 200+ Medical Devices 530+ Sales Associates 3000+ Employee Base 12 Manufacturing Plants Across 4 countries 334 Patents Granted 12 Specialities 1.8 Billion+ Devices Manufacturing Capacity Per year 125+ Countries 900+ Distributors across India & Globally 22
Page 23
Navigating Our Journey Polymed’s Path of Milestones and Triumphs 1997 Commencement of Manufacturing Operations 2004 2009 2014 2018 2003 Joint Venture in Assuit, Egypt Haridwar Plant Company listed in National Stock Exchange New R&D Center Faridabad Plant 2 China Plant – Poly Medicure (Laiyang) Co. Ltd Renal Care (Dialysis) New Plant in IMT Faridabad 4 New Plants expansion in Faridabad & Jaipur Gamma Sterilization Facility New plant in SEZ Jaipur 2020 2023 2025 2007 2011 2016 Cardiology & Critical Care Acquired Plan1 Health, Italy PolyHealth Medical Inc. (US subsidiary of Poly Medicure Ltd.) 2024 2021 2019 23
Page 24
Mr Himanshu Baid, MD, Poly Medicure EY Entrepreneur of the Year Award 2024 - Lifesciences & Healthcare Category Hurun India 2024 List of India's 500 Most Valuable Companies ET Best Healthcare Brands 2024 Top 75 Industrial Innovative Company of the Year 2024 by CII Indian Medical Devices Leader of the Year 2022 by Govt. of India Industrial Intellectual Property Awards 2024 by CII Top Exporter of Plastic Medical Disposables from India for 10 Years by Plexconcil The Next 500 Companies 2023 by Fortune India Himanshu Baid, MD, Poly Medicure Healthcare Entrepreneur of the Year 2025 by Financial Express Bhamashah Award by Govt. of Rajasthan, Education Dept. Medical Devices Provider of the Year 2025 by Financial Express Excellence in Medical Equipment Innovation by India Health Next Awards Awards & Accolades Leading Brand in Medical Devices by Elets 24
Page 25
2020-24 › Through a strategic focus on continuous innovation, global expansion, we will drive sustainable growth, enhance patient outcomes, and aim to solidify our presence in the medical device industry. 2025 - 27 › Prioritize the expansion of transformative verticals – Cardiology, Critical Care, Oncology, Renal Care › Expand global footprint with direct presence Supplier of 1st Choice Driving Delivery of Health Care Preferred Supplier Solutions Partner Commencement of Manufacturing Operation Product and facility expansion New R&D Center, Acq of Plan 1 Health, New Manufacturing Plants Started In 1997 2002-09 2011-19 Transition Navigating the Path Building Tomorrow’s Healthcare Solutions Value Based Supplier 2028 & beyond › Launched differentiated products in premium markets & geographies › Accelerate growth in developed markets 25
Page 26
Polymed’sEcosystem (Manufacturing Process) Tool Design Tool Manufacturing Product Manufacturing Product Packaging Sterilization Product Concept Product Design Rapid Prototyping Regulatory Compliance Clinical Support Distribution Network Sales & Marketing 26
Page 27
Our Innovations Deliver Care to Key Clinical Specialties Dialysis & Renal Care Oncology Anaesthesia & Respiratory Care Critical Care Diagnostics Infusion Therapy Cardiology Gastroenterology Urology Surgery & Wound Drainage Vascular Access Transfusion System 27
Page 28
Vascular Access IV Cannula Central Venous Catheters Peripherally Inserted Central Catheter Safety Introducer Needle Safety Winged Infusion Set Infusion Therapy Extension Lines with Needle Free Connectors Three Way Stop Cock with Extension Tube Vial Access Spike with Integrated Valve Oncology Implantable port PICC Catheter Infusion Set with Flow regulator Dialysis Blood Lines Dialyzer Dialysis System Fistula Needle Hemodialysis Catheter Transfusion System ACD Bag Single Blood Bag Multiple Blood Bag Umbilical Cord Bag Leuko Depletion Filter Bag Diagnostics Blood Collection Tubes Standard Needle Holder Blood Collection Needles Manifolds Arterial Blood Collection Syringe Disinfecting Cap Prefilled Saline Syringe Safety Huber Needle Needle Free Connectors Hemodialysis Kit Peritoneal Dialysis Set Peritoneal Dialysis Transfusion Set Transducer Protector Diving into our Product Portfolio VTM Kit Pre-filled Saline Syringe IV Sets Three Way Stop Cock Extension Lines HemodrawTransfer Bag Bedside Filter Photofusion IV set Oncofusion Infusion Set Scalpian Set 28
Page 29
Surgery and Wound Drainage Closed Wound Suction Unit High Pressure Vacuum Bottles Redon Drain Tubes Under Water Seal Drainage Thoracic Drainage Catheter Yankauer Section Set Urology Foley Ballon Catheters Urine Collection Bags Urine Drainage CathetersIrrigation Set Gastroenterology Enteral Connector Infant Feeding tube Levin’s Tube Ryle’s Tube Anesthesia & Respiratory Care Bain Circuits Catheter Mount Endotracheal Tubes Guedel Airway HME Filter Mucus Extractor Nebulizer Mask Oxygen Catheter Oxygen Mask Respiratory Exerciser Suction Catheter Nasal Oxygen Cannula Nebulizer Compressor System Critical Care Cardiology Mini Mid Lines - OTN Central Venous Catheters LA LineArterial Cannula Stopcock with Enteral Connector Feeding Bag Enteral Extension Set Leg Bag Set Urine Bag with T-type Bottom Outlet & Sampling Port Pediatric Urine Collection bag Diagnostic Catheter Hydrophilic Guidewire PTFE Coated Guidewire PTCA Balloon Dilation Catheter SC PTCA Balloon Dilation Catheter NC Guiding Catheter Closed Wound Suction Unit with Spring Yankauer Section Handle DES Umbilical Catheter Surfactant Catheter Arterial Catheter Centesis Catheter Enteral Syringe 29
Page 30
Polymed's Manufacturing Footprint 12 Facilities across 3 continents 117,Faridabad, India IMT 1,Faridabad, India 115-116, Faridabad Plant, India SEZ 1 Jaipur, India Laiyang-qingdao, China 104-105,Faridabad Plant, India R & D Centre, India Amaro, Italy Haridwar Plant, India Assuit, Egypt Company with international manufacturing facilities 350+ Moulding Machines and 1500+ Molds & Dies 200+ Automatic Assembly Machines 100+ Robots employed in our manufacturing processes 12 Plants SEZ 2, Jaipur, India IMT 2, Faridabad India *Confidential 30
Page 31
WayForward Implementing sustainable practices across all operations, aiming to minimize environmental impact Improve brand visibility & enhance direct presence to gain deeper insights into local market dynamics Enhance manufacturing capacity to meet growing global demand ▪ Targeted R&D investments towards transformative therapeutic areas, aiming towards innovations ▪ Integration of AI and IoT technologies to enhance efficiency & precisionStrategic Alliances to foster synergies and expanding market reach Research & Development Manufacturing Emphasizing Inorganic Growth International Strategy Clinical Footprint Protect Our Planet Targetedclinical engagements with key stakeholders, fostering innovation and enhancement of patient outcomes 31
Page 32
SUSTAINABLE DEVELOPMENT Towards our Commitment to a Sustainable World ▪ Annual Health check-up of 180 employees ▪ One on one consultation with certified nutritionist EMPLOYEE WELLBEING 33 Pits for Rain Harvesting to recharge ground water & 7 STPs provided to reuse the wastewater after treatment WATER CONSERVATION & RECYCLING Q1 FY 25- 764 MW Achieved 9% increase in onsite solar power generation ONSITE SOLAR POWER GENERATION Approx. 50% facilities are certified under ISO 14001:2015 ENVIRONMENTAL MANAGEMENT SYSTEM Achieved ~20% reduction in Scope 1 (Q1 FY25 vs. Q1 FY24) 9.9 MWp solar energy ▪ To achieve a ~28% reduction in scope-2 emission ▪ 30% cost saving SIGNED POWER PURCHASE AGREEMENT WITH AMPIN SCOPE 1 EMISSION ▪ Only Indian Member ▪ Help in Scope-3 emission reduction ZEMBA MEMBERSHIP (Q1 FY25 vs. Q1 FY24) 32
Page 33
Thank You For any investor related queries reach us at: aayur.verma@polymedicure.com 33